GE molecular diagnostics
This article was originally published in The Gray Sheet
Executive Summary
General Electric reaffirms its interest in supplementing imaging with in vitro diagnostics Oct. 1 with a three-year agreement with Eli Lilly to develop molecular assays that help target cancer therapies. The multiplexed tissue tests being developed at GE Healthcare and GE Global Research aim to identify protein and gene signatures to predict whether Eli Lilly's drugs will be effective. The collaboration follows the collapse of GE's planned buyout of part of Abbott's diagnostics business for $8 billion in July (1"The Gray Sheet" July 16, 2007, p. 3)